Samsung Bioepis Transfers Eye Care Biosimilar Sales Rights to US Firm

Samsung Bioepis transfers eye care biosimilar sales rights to US firm

Samsung Bioepis has transferred the commercial responsibility of its two ophthalmic biosimilars in the United States to a local pharmaceutical firm, the biotech firm said Friday. Samsung Bioepis entered into a license, development and commercialization agreement (DCA) with Harrow, a U.S. eye care drug specialist, transferring the commercialization rights of the former’s ophthalmology biosimilar drugs Byooviz and Opuviz in the U.S. Currently, the…

Harrow enters into agreement with Samsung Bioe for commercial rights to its ophthalmology biosimilar portfolio

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the US

Harrow announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, which includes Byooviz (ranibizumab-nuna), an FDA-approved biosimilar referencing Lucentis (ranibizumab), and Opuviz (aflibercept-yszy), an FDA-approved biosimilar referencing Eylea (aflibercept). Financial terms of the deal were not disclosed.  Byooviz ha…